CA1223815A - Blood plasma treating method and apparatus - Google Patents
Blood plasma treating method and apparatusInfo
- Publication number
- CA1223815A CA1223815A CA000463716A CA463716A CA1223815A CA 1223815 A CA1223815 A CA 1223815A CA 000463716 A CA000463716 A CA 000463716A CA 463716 A CA463716 A CA 463716A CA 1223815 A CA1223815 A CA 1223815A
- Authority
- CA
- Canada
- Prior art keywords
- plasma
- precipitate
- blood
- precipitating agent
- line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3441—Substitution rate control as a function of the ultrafiltration rate
- A61M1/3448—Substitution rate control as a function of the ultrafiltration rate by mechanically linked pumps in both ultra-filtrate and substitution flow line
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3479—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by dialysing the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
Treating blood by separating plasma from other blood components, adding a precipitating agent for precipitating plasma components to the plasma to form a precipitate, removing the precipitate from the plasma, removing the precipitating agent from the plasma, and mixing the other blood components with the treated plasma.
Treating blood by separating plasma from other blood components, adding a precipitating agent for precipitating plasma components to the plasma to form a precipitate, removing the precipitate from the plasma, removing the precipitating agent from the plasma, and mixing the other blood components with the treated plasma.
Description
~ZZ3815 ~20~-8 The inven~ion relates to treating blood plasma.
It is sometimes desirable to remove substances from blood plasma to harvest desirable substances from donors or to remove undesirable substances from a patient's blood.
For example Tsuda et al. United States Patent No.4,243,532 discloses continuously treating plasma separated from a patient's blood cells by causing it to flow past a purifying agent to which impurities are adsorbed (e.g.
activated carbon, alumina, silica, alumina-silica, zirconium phosphate, zeolite, ion-exchange resin), mixing the treated plasma with the separated blood cells and returning it to the patient.
I have discovered that blood plasma separated from other blood components can be advantageously treated by adding an agent for precipitating plasma components to the plasma to form a precipitate, removing the precipitate from the plasma, and removing the precipitating agent from the plasma, prior to mixing it with the separated components.
According to OTle aspect of the present invention there is provided a method for treating a sample of blood plasma comprising:
separating said plasma from other blood components, adding a precipitating agent for precipitating plasma components to said plasma to form a precipitate, removing the precipitate from the plasma, removing the precipitating agent from the plasma, and mixing said other blood components with said plasma to provide a mixture of treated plasma and other blood components.
According to another aspect of the present invention there is provided an apparatus for treating a patient's blood comprising:
means for continuously receiving plasma components separated from other blood components, means for adding a precipitating agent for precipitating plasma components to said plasma to form a precipitate, means for removing the precipitate from the plasma, means for removing the precipitating agent from the plasma, and means for continuously returning said plasma for mixing with said other blood components to provide a mixture of treated plasma and other blood components.
In preferred embodiments the precipitating agent is a salt (most preferably Na2S04); immunoglobulins are precipitated; blood is continuously removed from a patient, and the treated plasma is continuously mixed with the separated blood components and returned to the patient.
- la -The precipitating agent can be added to the plasma directly or by dialysis, to affect precipitate formation; a make-up fluid can be added to the treated plasma prior to returning it to the patient, and the precipitate concentration can be monitored by measuring the optical density of the plasma after the agent has been added and before the precipitate has been removed.
The preferred apparatus includes a microporous membrane device to separate the plasma from other blood components, a microporous membrane filter for removing the precipi~ate, a dialyzer for removing the precipitating agent and excess water, and a bypass shunt valve for directing separated plasma directly to a return line in the event that the conductivity of the treated plasma is not within acceptable limits.
The structure and operation of a preferred embodiment of the invention will now be described, after first briefly describing the drawing, which is a diagram of an apparatus for treating blood plasma according to the invention.
Referring to the drawingl there is shown apparatus 10 for continuously treating blood Bi provided by a patient via line 12 and for returning treated blood Bo via line 14. Line 12 is connected via peristaltic blood pump 16 to membrane separator 18, which provides plasma P at outlet 20 and concentrated mixture Bc of other blood components at outlet 22.
1223~5 Both plasma line 24, connected to plasma outlet 20, and line 26, connected to a source of 24 gm/100 ml Na2SO4 salt precipitating agent S, pass through double-line peristaltic pump 28, the inner diameter of lines 24, 26 being chosen to provide a ratio of Na2SO4 flow to plasma flow of-3~9 to 1. After pump 28, plasma line 24 passes through shunt valve 30 (causing plasma line 24 to be directly connected to ~
~ return line 14 in a bypass condition) and ~oins line 26 at junction 32, at which precipitate Ppt including immunoglobulins forms upon~the mixing of plasma P and
It is sometimes desirable to remove substances from blood plasma to harvest desirable substances from donors or to remove undesirable substances from a patient's blood.
For example Tsuda et al. United States Patent No.4,243,532 discloses continuously treating plasma separated from a patient's blood cells by causing it to flow past a purifying agent to which impurities are adsorbed (e.g.
activated carbon, alumina, silica, alumina-silica, zirconium phosphate, zeolite, ion-exchange resin), mixing the treated plasma with the separated blood cells and returning it to the patient.
I have discovered that blood plasma separated from other blood components can be advantageously treated by adding an agent for precipitating plasma components to the plasma to form a precipitate, removing the precipitate from the plasma, and removing the precipitating agent from the plasma, prior to mixing it with the separated components.
According to OTle aspect of the present invention there is provided a method for treating a sample of blood plasma comprising:
separating said plasma from other blood components, adding a precipitating agent for precipitating plasma components to said plasma to form a precipitate, removing the precipitate from the plasma, removing the precipitating agent from the plasma, and mixing said other blood components with said plasma to provide a mixture of treated plasma and other blood components.
According to another aspect of the present invention there is provided an apparatus for treating a patient's blood comprising:
means for continuously receiving plasma components separated from other blood components, means for adding a precipitating agent for precipitating plasma components to said plasma to form a precipitate, means for removing the precipitate from the plasma, means for removing the precipitating agent from the plasma, and means for continuously returning said plasma for mixing with said other blood components to provide a mixture of treated plasma and other blood components.
In preferred embodiments the precipitating agent is a salt (most preferably Na2S04); immunoglobulins are precipitated; blood is continuously removed from a patient, and the treated plasma is continuously mixed with the separated blood components and returned to the patient.
- la -The precipitating agent can be added to the plasma directly or by dialysis, to affect precipitate formation; a make-up fluid can be added to the treated plasma prior to returning it to the patient, and the precipitate concentration can be monitored by measuring the optical density of the plasma after the agent has been added and before the precipitate has been removed.
The preferred apparatus includes a microporous membrane device to separate the plasma from other blood components, a microporous membrane filter for removing the precipi~ate, a dialyzer for removing the precipitating agent and excess water, and a bypass shunt valve for directing separated plasma directly to a return line in the event that the conductivity of the treated plasma is not within acceptable limits.
The structure and operation of a preferred embodiment of the invention will now be described, after first briefly describing the drawing, which is a diagram of an apparatus for treating blood plasma according to the invention.
Referring to the drawingl there is shown apparatus 10 for continuously treating blood Bi provided by a patient via line 12 and for returning treated blood Bo via line 14. Line 12 is connected via peristaltic blood pump 16 to membrane separator 18, which provides plasma P at outlet 20 and concentrated mixture Bc of other blood components at outlet 22.
1223~5 Both plasma line 24, connected to plasma outlet 20, and line 26, connected to a source of 24 gm/100 ml Na2SO4 salt precipitating agent S, pass through double-line peristaltic pump 28, the inner diameter of lines 24, 26 being chosen to provide a ratio of Na2SO4 flow to plasma flow of-3~9 to 1. After pump 28, plasma line 24 passes through shunt valve 30 (causing plasma line 24 to be directly connected to ~
~ return line 14 in a bypass condition) and ~oins line 26 at junction 32, at which precipitate Ppt including immunoglobulins forms upon~the mixing of plasma P and
2 4 t S.
Plasma/salt line 34 connects junction 32 to precipitate filter 36, similar in constr~ction to the pleated membrane dialyzer shown in U.S. Patent No.
4,239,625 except that a microporous membrane approximately 0.17 mm thick, and having an average pore size of 0.6 micron is used, there are Vexar spacers on both sides of the pleated membrane, and the tips of the membrane folds need not be potted. The plasma flows in - a blood port and out a dialysate port (at the other end of the dialyzer), and the remaining blood port and dialysate port are blocked.
Downstream of precipitate filter 36 is precipitating-agent-removing dialyzer system 38, three serially-connected dialyzers each similar in construction to that shown in U.S. Patent No. 4,239,625, except that in the first two dialyzers the membranes are Enka 280 HDF l.9-square meter high-flux membranes.
Dialyzer sy6tem 38 is connected to dialysate preparàtion and supply apparatus (e.g., similar to the Centry 2 system of Cobe Laboratories, Lakewood, Colorado, shown in U.S. Patent No. 3,990,973). The dialysate is similar to standard dialysate.
~22:~1S`
Downstream of dialyzer system 38 is double-line peristaltic return pump 40, through which plasma line 42 and make-up fluid line 44 both pass~ Lines 42, 44 are of the same size, so that there will be equal flow rates through each when both are unclamped. On line 44 there is air detector 46 and valve 48, used to prevent flow through line 44 when make up fluid is not being added. Lines 42, 44 join at junction 50, connected by line 52 to junction 54 via shunt valve 30 (which, in the bypass condi-tion, in addition to connecting plasma line 24 to return line 14, also connects line 52 to junction 32). Return line 14 is connected to junction 54.
Collection bag connecting lines 56, 58 and associated valves 60, 62 are provided on lines 34, 42 for taking samples.
Conductivity sensor 64 is provided on line 42.
In operation, a patient is connected to lines 12, 14.
Blood pump 16, double-line plasma pump 28, return pump 40 and separator 18 are controlled to provide the desired separation of plasma and blood cells in separator 18 without damage to the cells. At junction 32, 3.9 parts of 24 gm/100 ml Na2SO4 are diluted by one part of plasma to result in approximately 19 gm/100 ml Na2SO4 in the plasma/salt combination in line 34. At this Na2SO4 concentration, immunoglobulin and other protein precipitates form quickly, and the precipitates are filtered out at precipitate filter 36, which has sufficient capacity, owing to its spacers on the upstream side of the membrane, to collect the immunoglobulin precipitate 12238iS
removed durin~ treatment of a single patient with normal immunoglobulin concentrations. The Na2SO4 and excess water (caused by mixing 3.9 parts of salt solution with one part plasma at junction 32) are removed at dialyzer system 38, and the treated plasma is pumped via pump 40 to jUnCtiQn 54, where it mixes with the high blood cell concentration mixture sc and is returned to the patient. Pump 40 is operated at a rate related to that of pump 28, typically at ~he same rate i~ valve 48 is closed or at one half the rate of pump 28 if valve:48 is open, so th~at the volume returned to the patient is the same as that removed. The rate of pump 40 can also be varied to affect the ultrafiltration achieved in dialysis sytem 38.
- If during operation an improper conductivity is sensed by sensor 64, shunt valve 30 is activated to direct plasma in line 24 directly to junction 54 and to connect line 52 to junction 32.
In the presently most preferred embodiment, the treating apparatus does not include the means for separating plasm~ from other blood components but is instead designed for connection to Cobe Laboratories Therapeutic Plasma Exchange System (TPE) described in the above-mentioned patent appllcation. In this embodiment, plasma line 24 is connected to receive plasma fro~ the plasma pump of the TPE system; line 52 is connected to the junction of the TPE system corresponding to junction 54, and shunt valve 30 is replaced by a shunt valve between line 24 upstream of 12Z:~8~S
pump 28 and line 52. This embodiment could also be used with other means for separatin~ plasma from other blood components.
Also, other precipitating agents or other concentrations can be used to affect the types of precipitates that form. Othe~r 6alts reported to precipitate proteins are those that include ions in the Hofmeister series, incl~lding S042, P043, F 1, Cl 1, Br~l, I-l, NO31, C1041, CNS 1 (listed in decreasing ability to promote precipitation; Franks, F., "Solvent Mediated Influence on Conformation and Activity of Proteins", p. 45 (Symposium Press, London). Also, the precipitating agent can be added more gradually, e.g., by usinq a dialyzer instead of junction 32, to affect the formation of precipitates. Also, other means can be used to remove the precipitate and precipitating agent or to separate plasma from the other blood components.
Plasma/salt line 34 connects junction 32 to precipitate filter 36, similar in constr~ction to the pleated membrane dialyzer shown in U.S. Patent No.
4,239,625 except that a microporous membrane approximately 0.17 mm thick, and having an average pore size of 0.6 micron is used, there are Vexar spacers on both sides of the pleated membrane, and the tips of the membrane folds need not be potted. The plasma flows in - a blood port and out a dialysate port (at the other end of the dialyzer), and the remaining blood port and dialysate port are blocked.
Downstream of precipitate filter 36 is precipitating-agent-removing dialyzer system 38, three serially-connected dialyzers each similar in construction to that shown in U.S. Patent No. 4,239,625, except that in the first two dialyzers the membranes are Enka 280 HDF l.9-square meter high-flux membranes.
Dialyzer sy6tem 38 is connected to dialysate preparàtion and supply apparatus (e.g., similar to the Centry 2 system of Cobe Laboratories, Lakewood, Colorado, shown in U.S. Patent No. 3,990,973). The dialysate is similar to standard dialysate.
~22:~1S`
Downstream of dialyzer system 38 is double-line peristaltic return pump 40, through which plasma line 42 and make-up fluid line 44 both pass~ Lines 42, 44 are of the same size, so that there will be equal flow rates through each when both are unclamped. On line 44 there is air detector 46 and valve 48, used to prevent flow through line 44 when make up fluid is not being added. Lines 42, 44 join at junction 50, connected by line 52 to junction 54 via shunt valve 30 (which, in the bypass condi-tion, in addition to connecting plasma line 24 to return line 14, also connects line 52 to junction 32). Return line 14 is connected to junction 54.
Collection bag connecting lines 56, 58 and associated valves 60, 62 are provided on lines 34, 42 for taking samples.
Conductivity sensor 64 is provided on line 42.
In operation, a patient is connected to lines 12, 14.
Blood pump 16, double-line plasma pump 28, return pump 40 and separator 18 are controlled to provide the desired separation of plasma and blood cells in separator 18 without damage to the cells. At junction 32, 3.9 parts of 24 gm/100 ml Na2SO4 are diluted by one part of plasma to result in approximately 19 gm/100 ml Na2SO4 in the plasma/salt combination in line 34. At this Na2SO4 concentration, immunoglobulin and other protein precipitates form quickly, and the precipitates are filtered out at precipitate filter 36, which has sufficient capacity, owing to its spacers on the upstream side of the membrane, to collect the immunoglobulin precipitate 12238iS
removed durin~ treatment of a single patient with normal immunoglobulin concentrations. The Na2SO4 and excess water (caused by mixing 3.9 parts of salt solution with one part plasma at junction 32) are removed at dialyzer system 38, and the treated plasma is pumped via pump 40 to jUnCtiQn 54, where it mixes with the high blood cell concentration mixture sc and is returned to the patient. Pump 40 is operated at a rate related to that of pump 28, typically at ~he same rate i~ valve 48 is closed or at one half the rate of pump 28 if valve:48 is open, so th~at the volume returned to the patient is the same as that removed. The rate of pump 40 can also be varied to affect the ultrafiltration achieved in dialysis sytem 38.
- If during operation an improper conductivity is sensed by sensor 64, shunt valve 30 is activated to direct plasma in line 24 directly to junction 54 and to connect line 52 to junction 32.
In the presently most preferred embodiment, the treating apparatus does not include the means for separating plasm~ from other blood components but is instead designed for connection to Cobe Laboratories Therapeutic Plasma Exchange System (TPE) described in the above-mentioned patent appllcation. In this embodiment, plasma line 24 is connected to receive plasma fro~ the plasma pump of the TPE system; line 52 is connected to the junction of the TPE system corresponding to junction 54, and shunt valve 30 is replaced by a shunt valve between line 24 upstream of 12Z:~8~S
pump 28 and line 52. This embodiment could also be used with other means for separatin~ plasma from other blood components.
Also, other precipitating agents or other concentrations can be used to affect the types of precipitates that form. Othe~r 6alts reported to precipitate proteins are those that include ions in the Hofmeister series, incl~lding S042, P043, F 1, Cl 1, Br~l, I-l, NO31, C1041, CNS 1 (listed in decreasing ability to promote precipitation; Franks, F., "Solvent Mediated Influence on Conformation and Activity of Proteins", p. 45 (Symposium Press, London). Also, the precipitating agent can be added more gradually, e.g., by usinq a dialyzer instead of junction 32, to affect the formation of precipitates. Also, other means can be used to remove the precipitate and precipitating agent or to separate plasma from the other blood components.
Claims (32)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method for treating a sample of blood plasma comprising:
separating said plasma from other blood components, adding a precipitating agent for precipitating plasma components to said plasma to form a precipitate, removing the precipitate from the plasma, removing the precipitating agent from the plasma, and mixing said other blood components with said plasma to provide a mixture of treated plasma and other blood components.
separating said plasma from other blood components, adding a precipitating agent for precipitating plasma components to said plasma to form a precipitate, removing the precipitate from the plasma, removing the precipitating agent from the plasma, and mixing said other blood components with said plasma to provide a mixture of treated plasma and other blood components.
2. The method of claim 1 wherein said precipitating agent is a salt.
3. The method of claim 2 wherein said removing the precipitating agent comprises removing by dialysis and removing excess liquid by ultrafiltration.
4. The method of claim 2 wherein said removing the precipitate is removing by filtration.
5. The method of claim 4 wherein said filtration is filtration with a microporous membrane.
6. The method of claim 1 further comprising continuously removing blood from a patient prior to said separating, and continuously returning said treated plasma and other blood components to said patient.
7. The method of claim 6 wherein said separating is separating with a microporous membrane.
8. The method of claim 2 wherein said precipitate comprises immuno-globulins.
9. The method of claim 2 wherein said adding comprises mixing a solution of said agent with said plasma.
10. The method of claim 2 wherein said adding an agent comprises dialysis.
11. The method of claim 1 further comprising harvesting said precipitate.
12. The method of claim 2 wherein said salt includes SO4-2.
13. The method of claim 12 wherein said salt comprises Na2SO4.
14. The method of claim 6 further comprising adding a make-up fluid prior to said returning.
15. The method of claim 9 wherein said adding comprises pumping said plasma and said salt through two lines via a single peristaltic pump.
16. The method of claim 1 wherein said adding comprises pumping said plasma and said precipitating agent through two lines via a single peristaltic pump, and said mixing comprises pumping an amount of treated plasma at a rate that is a constant multiple of the plasma pumping rate.
17. The method of claim 2 further comprising monitoring the conductivity of said plasma after said precipitating agent has been removed and activating a bypass valve to avoid said adding and removing in the event of an improper conductivity.
18. An apparatus for treating a patient's blood comprising:
means for continuously receiving plasma components separated from other blood components, means for adding a precipitating agent for precipitating plasma components to said plasma to form a precipitate, means for removing the precipitate from the plasma, means for removing the precipitating agent from the plasma, and means for continuously returning said plasma for mixing with said other blood components to provide a mixture of treated plasma and other blood components.
means for continuously receiving plasma components separated from other blood components, means for adding a precipitating agent for precipitating plasma components to said plasma to form a precipitate, means for removing the precipitate from the plasma, means for removing the precipitating agent from the plasma, and means for continuously returning said plasma for mixing with said other blood components to provide a mixture of treated plasma and other blood components.
19. The apparatus of claim 18 further comprising means for separating said plasma from said other blood components.
20. The apparatus of claim 18 wherein said means for adding a precipitating agent is means for adding a salt solution.
21. The apparatus of claim 20 wherein said means for removing the precipitating agent is a dialyzer.
22. The apparatus of claim 20 wherein said means for removing the precipitate comprises a filter.
23. The apparatus of claim 22 wherein said filter comprises a microporous membrane.
24. The apparatus of claim 19 further comprising means for continuously removing blood from a patient and supplying it to said means for separating, and means fpr continuously providing said treated plasma and other blood components to said patient.
25. The apparatus of claim 24 wherein said means for separating comprises a microporous membrane.
26. The apparatus of claim 20 wherein said precipitate comprises immunoglobulins.
27. The apparatus of claim 20 wherein said means for adding comprises means for mixing a solution of said agent with said plasma.
28. The apparatus of claim 20 wherein said means for adding is a dialyzer.
29. The apparatus of claim 18 wherein said means for adding comprises a peristaltic pump receiving a plasma line and a salt solution line that join together downstream of said pump.
30. The apparatus of claim 20 further comprising a conductivity monitor to measure the conductivity of plasma downstream of said means for removing the precipitating agent and a bypass shunt valve to bypass said means for adding and measuring in response to the sensed conductivity.
31. The apparatus of claim 24 further comprising a make-up fluid line joining said plasma line between said means for removing and said means for mixing.
32. The apparatus of claim 31 further comprising a peristaltic pump receiving said plasma line and said make-up fluid line, and wherein said plasma line and said make-up fluid line join together downstream of said pump, and a valve on said make-up fluid line upstream of said pump.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53515183A | 1983-09-23 | 1983-09-23 | |
| US535,151 | 1983-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1223815A true CA1223815A (en) | 1987-07-07 |
Family
ID=24133053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000463716A Expired CA1223815A (en) | 1983-09-23 | 1984-09-21 | Blood plasma treating method and apparatus |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS6092770A (en) |
| CA (1) | CA1223815A (en) |
| DE (1) | DE3434755A1 (en) |
| FR (1) | FR2552329A1 (en) |
| GB (1) | GB2150572A (en) |
| IT (1) | IT8467950A0 (en) |
| NL (1) | NL8402870A (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6099265A (en) * | 1983-11-07 | 1985-06-03 | テルモ株式会社 | Protein removing apparatus of body fluids |
| JPS6099266A (en) * | 1983-11-07 | 1985-06-03 | テルモ株式会社 | Removal of protein in body fluids and apparatus used therein |
| US4678566A (en) * | 1984-07-20 | 1987-07-07 | Terumo Kabushiki Kaisha | Apparatus for separating proteins from blood plasma |
| JPS62266071A (en) * | 1986-05-14 | 1987-11-18 | テルモ株式会社 | Plasma protein separator |
| AU2001232053A1 (en) * | 2000-02-11 | 2001-08-20 | Allied Therapeutics Limited | System for the extracorporeal treatment of blood |
-
1984
- 1984-09-19 NL NL8402870A patent/NL8402870A/en not_active Application Discontinuation
- 1984-09-21 CA CA000463716A patent/CA1223815A/en not_active Expired
- 1984-09-21 DE DE19843434755 patent/DE3434755A1/en not_active Withdrawn
- 1984-09-21 GB GB08423907A patent/GB2150572A/en not_active Withdrawn
- 1984-09-21 IT IT8467950A patent/IT8467950A0/en unknown
- 1984-09-24 FR FR8414619A patent/FR2552329A1/en not_active Withdrawn
- 1984-09-25 JP JP59200316A patent/JPS6092770A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB8423907D0 (en) | 1984-10-31 |
| DE3434755A1 (en) | 1985-06-13 |
| NL8402870A (en) | 1985-04-16 |
| GB2150572A (en) | 1985-07-03 |
| JPS6092770A (en) | 1985-05-24 |
| IT8467950A0 (en) | 1984-09-21 |
| FR2552329A1 (en) | 1985-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4411792A (en) | Lymph filtration system | |
| US5431811A (en) | Artificial kidney with device for filtering dialysis liquid | |
| KR101044980B1 (en) | Method and device for the removal of partially protein bound substances | |
| EP2800592B1 (en) | Multi-staged filtration system for blood fluid removal | |
| AU604054B2 (en) | Blood cell washing systems and methods | |
| CN1761494B (en) | Blood treatment device by selective solute extraction | |
| EP0549341A1 (en) | Hollow fiber plasma sampler | |
| EP1809410B1 (en) | Ionic enhanced dialysis/disfiltration system | |
| US20050006296A1 (en) | Sorbent reactor for extracorporeal blood treatment systems, peritoneal dialysis systems, and other body fluid treatment systems | |
| JP2002521162A (en) | Efficient hemodiafiltration | |
| EP0156496B1 (en) | Apparatus for the treatment of plasma | |
| JP2004512873A (en) | Two-stage diafiltration method and apparatus | |
| WO1997032653A1 (en) | Selective membrane/sorption techniques for salvaging blood | |
| WO1999042150A1 (en) | Hemofiltration system including ultrafiltrate purification and re-infusion system | |
| JP4436569B2 (en) | Permeation type filtration system by osmotic pressure difference | |
| JP2006508721A5 (en) | ||
| JPH08295630A (en) | Plasma separation | |
| JP2020533159A (en) | How to treat protein-containing suspensions or protein-containing solutions | |
| US4968432A (en) | Treatment of liquid including blood components | |
| CA1223815A (en) | Blood plasma treating method and apparatus | |
| EP0056855A2 (en) | Preparation of infusion grade water | |
| US5057226A (en) | Treatment of liquid including blood components | |
| US20170266362A1 (en) | System for removal of pro-inflammatory mediators as well as granulocytes and monocytes from blood | |
| Erley et al. | Easy production of sterile, pyrogen-free dialysate | |
| JPS6362B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |